Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells $437,550.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of iRadimed stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $87.51, for a total transaction of $437,550.00. Following the sale, the chief executive officer owned 2,175,000 shares in the company, valued at approximately $190,334,250. This trade represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

Shares of iRadimed stock opened at $92.10 on Friday. The firm’s 50-day simple moving average is $92.74 and its 200-day simple moving average is $95.10. iRadimed Corporation has a twelve month low of $50.88 and a twelve month high of $107.90. The firm has a market cap of $1.18 billion, a P/E ratio of 50.33 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities analysts forecast that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be given a $0.20 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is 43.72%.

Analyst Ratings Changes

IRMD has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Lake Street Capital restated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Roth Mkm restated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $120.00.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently modified their holdings of IRMD. Royal Bank of Canada raised its stake in shares of iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of iRadimed by 7.5% during the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 1,108 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after buying an additional 234 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after buying an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after buying an additional 1,821 shares during the last quarter. 92.34% of the stock is owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.